Clinical Trial Update: A Phase 2, Randomized, Open-Label Study Of Single Agent CI-1033 In Patients With Advanced Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Pfizer completed a Phase 2 randomized, open-label study of CI-1033 as a single agent in patients with advanced non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CI-1033

Snippet

Sponsor: Pfizer | Conditions: Lung Neoplasms | Phase 2 | Status: COMPLETED